reference/24416131

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/24416131

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	228
issn	0923-7534
issueIdentifier	2
pageRange	218-228
publicationName	Annals of oncology : official journal of the European Society for Medical Oncology
startingPage	218
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_73b36fde15b0d91432e5cf9a015a48a8
bibliographicCitation	Xu B, Sun T, Zhang Q, Zhang P, Yuan Z, Jiang Z, Wang X, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Shen K, Yu S, Li H, Tang L, Qiu R; study group of BG01-1323L. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. Ann Oncol. 2021 Feb;32(2):218–28. doi: 10.1016/j.annonc.2020.10.600. PMID: 33188874.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db5d2f393f5eeea87b0ca3d0501550b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40c606c926a39bea91ab93c555020817 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5342e1d8c4f4133c4ce19fdbe57b6b5c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3bfe2ec263c20818ab41e47653745ad9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f43f539efc00f870645d1eca0c90c24a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31ab7582647812779f9f9b3fc2de6bc9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a2af5979d646bd09c4e479529aa1d8f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6211825963367314b7297577cab15ee2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_82cca5495746c6d9444350184721a688 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a67d3a4b38c789eef17e6fc12ae9609 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_205d1953b44cbcfe9bc9784945b71d14 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e85c95ba8fc27a6686290e6b77712268 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3276245560ceea09dcad896d7d8d3a76 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f6204a4795cc017f9e576d282a2f90f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7ef9db9beaa84a8d59fd7098a35121cd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d4dcd685716b865420fe5f17cc1bce5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ccd52a3710b05fe8513df204df21fe42 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1483806d2e6c0a0e23375c0322fe63df http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efc774fee58aa19f4237b4cd72c98017 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d9d090190a504fd2c5f72ca745e0e34 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c1325da3c4e8c9c48d99d9f51c3975d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9c5db1132bb39ec1063698c9365cc6c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3c0cc5f14e6cd6c8b511ab5f8536eb5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc62419f1146b128813904c7c71bb43c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1f7aaa0fde87e9caec4084d41519272a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c99ff551e8c835be89fea5bd911cc1d0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b8d5cd43f884238f152d1f6153357c88 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3ff05d8b4da0cb8ae4491940b8cd7f2f
date	202102
identifier	https://doi.org/10.1016/j.annonc.2020.10.600 https://pubmed.ncbi.nlm.nih.gov/33188874
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1846 https://portal.issn.org/resource/ISSN/0923-7534
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial
discusses	http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M0008631 http://id.nlm.nih.gov/mesh/M0028312 http://id.nlm.nih.gov/mesh/M0287377
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D018943Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D043823Q000627 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D000069287Q000627 http://id.nlm.nih.gov/mesh/D005472Q000627
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9548828 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9d7fe60f25abdf582afc7cdca238bde8 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60953 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7ed75134b36b0e173fb44798462e4e66 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102

Showing number of triples: 1 to 67 of 67.